Stay updated on Nivolumab for High-Risk Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.

Latest updates to the Nivolumab for High-Risk Prostate Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRecruitment status updated to 'No longer looking for participants' and new help sections added (How to Read a Study Record, Common Questions, How to Join a Study). A header label related to Intervention/Treatment was adjusted and the revision footer updated to v3.6.0.SummaryDifference0.4%

- Check21 days agoChange DetectedNew related topics such as Prostate cancer and MedlinePlus Genetics were added to the page, and the site revision was updated from v3.5.4 to v3.5.5. These changes update metadata and navigation references without altering the study content or results shown on the page.SummaryDifference0.2%

- Check42 days agoChange DetectedThe study record now includes a Results Posted entry and updates to several primary and secondary outcomes (e.g., disease control rate at 12 weeks, PSA dynamics, radiographic progression, and treatment-related adverse events) along with related documents. Several older PSA-related outcomes were removed.SummaryDifference3%

- Check50 days agoChange DetectedAdds related-topic references for Prostate cancer and MedlinePlus Genetics to the page, improving quick access to background resources related to the study.SummaryDifference0.2%

- Check57 days agoChange DetectedThe Study Record Dates section now shows Revision: v3.5.3 replacing v3.5.2, indicating an updated page revision. This reflects an administrative update to the record rather than changes to study information.SummaryDifference0.1%

- Check71 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 in the page footer. No other visible changes to trial details or content.SummaryDifference0.1%

Stay in the know with updates to Nivolumab for High-Risk Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.